TriCalm Hydrogel in the Treatment of Immunotherapy-Related Pruritus
Status:
RECRUITING
Trial end date:
2028-12-01
Target enrollment:
Participant gender:
Summary
This is a phase 2, randomized, open-label, single-center study that will assess the efficacy of TriCalm Hydrogel, a topical gel containing strontium, for treating pruritus related to immune checkpoint inhibitors (ICIs).